A clinical prediction tool to determine the need for concurrent systematic sampling at the time of MRI ‐guided biopsy

ConclusionWe found that omitting concurrent systematic biopsy in men undergoing TRUS/MRI fusion guided biopsy would miss significant disease in more than one in ten patients. We propose a prediction model with good discriminative ability that can be used to improve patient selection for performing concurrent systematic biopsy in order to minimize the number of missed significant cancers. It is important that our model is validated in external cohorts before being employed in routine clinical practice.This article is protected by copyright. All rights reserved.
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research